PDS Biotechnology Post-ASCO Conference Call Tomorrow, June 6, at 8 a.m. ET
June 05 2023 - 2:52PM
PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage
immunotherapy company developing a growing pipeline of targeted
immunotherapies for cancer and infectious disease, today announced
that the Company will be hosting a conference call and webcast
tomorrow, June 6, 2023, to discuss the promising interim data from
the VERSATILE-002 (NCT04260126) Phase 2 clinical trial
investigating PDS0101 in combination with Merck’s anti-PD-1
therapy, KEYTRUDA® (pembrolizumab), presented at the 2023 American
Society for Clinical Oncology (ASCO) meeting.
During the call, management will provide an
in-depth review of the 2023 ASCO interim data.
Conference Call Information:PDS
Biotech will host a conference call on Tuesday, June 6, at 8:00
a.m. ET to discuss the interim data being presented at the ASCO
2023 Annual Meeting. A live webcast of the event will be available
online at PDS Biotech Post-ASCO Webcast. The event will be archived
in the investor relations section of PDS Biotech’s website for six
months.
Additionally, interested participants and
investors may access the conference call by dialing either
877-407-3088 (US) or 201-389-0927 (International).
About PDS BiotechnologyPDS
Biotech is a clinical-stage immunotherapy company developing a
growing pipeline of targeted cancer and infectious disease
immunotherapies based on our proprietary Versamune®, Versamune®
plus PDS0301, and Infectimune™ T cell-activating platforms. We
believe our targeted immunotherapies have the potential to overcome
the limitations of current immunotherapy approaches through the
activation of the right type, quantity and potency of T cells. To
date, our lead Versamune® clinical candidate, PDS0101, has
demonstrated the ability to reduce and shrink tumors and stabilize
disease in combination with approved and investigational
therapeutics in patients with a broad range of HPV16-associated
cancers in multiple Phase 2 clinical trials and will be advancing
into a Phase 3 clinical trial in combination with KEYTRUDA® for the
treatment of recurrent/metastatic HPV16-positive head and neck
cancer in 2023. Our Infectimune™ based vaccines have also
demonstrated the potential to induce not only robust and durable
neutralizing antibody responses, but also powerful T cell
responses, including long-lasting memory T cell responses in
pre-clinical studies to date. To learn more, please visit
www.pdsbiotech.com or follow us on Twitter at
@PDSBiotech.
Investor Relations:Deanne
RandolphPDS BiotechPhone: +1 (908) 517-3613Email:
drandolph@pdsbiotech.com
Rich CockrellCG CapitalPhone: +1 (404)
736-3838Email: pdsb@cg.capital
Media Contacts:Tiberend
Strategic Advisors, Inc.Dave SchemeliaPhone: +1 (609)
468-9325dschemelia@tiberend.com
Bill BordenPhone: +1 (732)
910-1620bborden@tiberend.com
PDS Biotechnology (NASDAQ:PDSB)
Historical Stock Chart
From Mar 2024 to Apr 2024
PDS Biotechnology (NASDAQ:PDSB)
Historical Stock Chart
From Apr 2023 to Apr 2024